This review covers the current treatment landscape for MS and its limitations, the basic science of TNFR2, and the rationale for TNFR2 agonism for treating multiple sclerosis and other neurological, autoimmune, or inflammatory diseases. Here, TNFRSF1B is linked to myeloid sarcoma.